The dystrophin restoration drugs are approved conditionally in the US for the treatment of approximately a third of ambulant DMD patients with mutations to dystrophin exons 45, 51, and 53. As an indication of the potential market for dystrophin restoration drugs , Sarepta Therapeutics Ltd recently announced preliminary net product revenues for the fourth quarter and full-year 2022 are expected to total US$235.5 million and US$843.3 million, respectively for their 3 approved exon restoration drugs in the US alone.
if we have a patent on our drug with Sarepta's, does that mean we hold all the power.... for them to use our discovery? Or would it be some kind of combo patent... questions for the next announcement perhaps.
1billion a year keeps getting referenced, to my satisfaction, shows confidence in understanding the market value.
